Browse the evidence

In patients with type 2 diabetes and baseline eGFR <80 mL/min/1.73 m2, intensive lifestyle intervention is associated with a slightly higher mean eGFR over 10 years compared to usual care, suggesting a potential benefit in preserving kidney function in this subgroup.

If your kidney function is already slightly reduced (eGFR <80), an intensive lifestyle program may help you maintain a slightly higher average kidney function level over 10 years compared to standard care. While it may not stop the decline entirely, it might offer a small protective benefit. Discuss this with your doctor to see if you are a candidate.

Compounded GLP-1 receptor agonists (semaglutide, tirzepatide) are widely marketed for weight loss in Colorado, but these products lack FDA approval for safety and efficacy, are often mislabeled as 'generic' or 'FDA-approved', and may contain unsafe additives like BPC-157 or unapproved salt forms.

Be aware that compounded GLP-1 drugs sold directly to consumers are not FDA-approved for safety or efficacy. They may contain impurities, incorrect doses, or unsafe additives like BPC-157. Marketing claims of 'FDA approval' or 'generic' status are misleading. Consult a healthcare provider to understand the risks and legal status of these products.

Subcutaneous administration of a semaglutide-rosuvastatin-lipid conjugate nanoparticle (SRLC NP) formulation significantly reduces body weight and improves liver function markers in high-fat diet-induced obese mice compared to conventional semaglutide or individual components.

This research describes a novel experimental nanoparticle formulation combining semaglutide with a statin-lipid conjugate. In obese mice, this specific formulation led to significant weight loss and liver health improvements compared to standard treatments. However, this is preclinical data; it is not a current treatment option for humans, and the safety and efficacy in people remain unproven.

Dihydromyricetin (DHM) supplementation improves insulin resistance and glucose tolerance in high-fat diet-induced mice by modulating gut microbiota to increase chenodeoxycholic acid (CDCA), which inhibits farnesoid X receptor (FXR) expression in intestinal L cells, thereby increasing glucagon gene (Gcg) mRNA expression and enhancing glucagon-like peptide-1 (GLP-1) secretion.

This research suggests that Dihydromyricetin (DHM), a compound found in plants like Ampelopsis grossedentata, may help improve insulin sensitivity and blood sugar control by changing gut bacteria to produce more beneficial bile acids (CDCA). This process boosts GLP-1, a hormone that helps regulate blood sugar. While this was shown in mice fed a high-fat diet, it points to the importance of gut health in metabolic function. For humans, this implies that dietary sources of DHM or gut-health-supporting strategies might be a complementary approach to managing insulin resistance, though human dosing and efficacy are not yet established.

Dysregulation of hypothalamic nuclei (specifically AgRP and POMC neurons in the arcuate nucleus) is a primary driver of obesity and type 2 diabetes through mechanisms involving insulin resistance, hyperphagia, and disrupted glucose sensing.

Metabolic diseases like obesity and diabetes are not just about willpower or peripheral fat storage; they involve critical signaling centers in the brain (the hypothalamus). When these signals (like leptin and insulin) are disrupted, it drives hunger and insulin resistance. This understanding supports the use of therapies that target these central pathways, such as GLP-1 receptor agonists, to help restore metabolic balance.

AgRP neuron hyperactivity contributes to chronic insulin resistance and obesity by inducing brown adipose tissue-derived myostatin expression, which systemically inhibits insulin signaling in skeletal muscle and white adipose tissue.

This mechanism explains why some individuals with obesity struggle with insulin resistance beyond just fat mass. It suggests that targeting the AgRP-myostatin pathway could be a therapeutic strategy, although current treatments focus more broadly on GLP-1 and MC4R pathways.

Tirzepatide reduces MC38 colon tumor growth rates in diet-induced obese mice by approximately 50%, but this effect is indirect and mediated by reduced food intake, lower insulin, and lower leptin levels rather than direct anti-proliferative action on cancer cells.

For obese individuals with early-stage, insulin-sensitive cancers (like colon cancer), tirzepatide may help slow tumor growth. This benefit appears to come from reducing insulin and leptin levels through weight loss and appetite suppression, not from directly attacking the cancer cells. It is not a cure, but it may improve outcomes by altering the metabolic environment that fuels cancer growth.

Ingestion of an isonitrogenous non-essential amino acid (NEAA) formulation does not stimulate muscle protein synthesis (MPS) or activate mTOR signaling pathways in skeletal muscle cells, making it an effective non-bioactive control for protein bioactivity studies.

If you are looking to stimulate muscle growth, consuming non-essential amino acids (NEAA) alone will not trigger the necessary biological signals. Muscle protein synthesis is driven by essential amino acids (EAAs), specifically leucine. Use NEAA as a control or filler in studies, but rely on complete proteins or EAAs for actual muscle building effects.

A two-meals-a-day ketogenic diet may cause an increase in serum uric acid levels in patients with type 2 diabetes.

Monitor uric acid levels when starting this diet, as it may rise. This is a known trade-off of ketosis.

Semaglutide 2.4 mg use is associated with significant side effects, including gastrointestinal distress and rare but severe complications like pancreatitis.

Be prepared for gastrointestinal side effects, especially when starting or increasing the dose. These often subside, but severe symptoms like pancreatitis require immediate medical attention.

Baseline gut microbiome composition predicts the efficacy of semaglutide and empagliflozin in reducing HbA1c, whereas the drugs themselves do not significantly alter microbial diversity or composition.

If you are starting semaglutide or empagliflozin for Type 2 Diabetes, your current gut bacteria might predict how much your blood sugar (HbA1c) will drop. The drugs themselves don't seem to drastically change your gut diversity, but knowing your baseline microbiome could help personalize your treatment. This is still early research, so discuss testing options with your doctor.

Phentermine is generally avoided in older adults due to risks of falls, anxiety exacerbation, and cardiovascular side effects, despite its efficacy in younger populations.

Phentermine is rarely recommended for older adults because it can cause dizziness (increasing fall risk), worsen anxiety, and strain the heart. It is generally avoided in this age group due to multiple comorbidities.

GLP-1 agonist pharmacotherapy for obesity in women may not be economically justified by healthcare cost savings alone, as the high lifetime cost of obesity is largely driven by reduced life expectancy rather than increased annual healthcare utilization.

For women with obesity, using GLP-1 medications like semaglutide or tirzepatide is a significant financial investment. Current economic models suggest that simply saving on annual medical bills for obesity-related conditions may not cover the drug costs. However, if the treatment successfully extends life expectancy by even 50% of the years lost to obesity, the long-term value to the healthcare system and the patient's quality of life can justify the expense.

DJB implantation leads to significant improvements in liver enzymes (AST, ALT, GGT) and lipid panels (LDL, Cholesterol, HDL, TAG).

DJB implantation improves liver health (reducing enzymes like AST and ALT) and improves lipid profiles (lowering bad cholesterol and triglycerides, raising good cholesterol).

Nanomedicine delivery systems can enhance the efficacy of glucose-lowering drugs by enabling site-specific delivery to macrophages, potentially inducing plaque regression.

This is currently a research area. While standard GLP-1 injections work, scientists are developing nanoparticle versions that might target heart plaques directly. This is not yet available for routine clinical use.

GLP-1 receptor agonists (semaglutide, tirzepatide) can cause excessive appetite suppression leading to restrictive eating behaviors, severe caloric restriction, dehydration, and acute kidney injury, particularly in unmonitored or high-risk populations.

If you are prescribed a GLP-1 agonist (like Ozempic or Mounjaro), do not use it without medical supervision. Ensure you are screened for eating disorders and receive dietary counseling. Watch for signs of extreme food aversion or dehydration, and stop the medication if you lose weight too rapidly or feel severe nausea/diarrhea, seeking immediate medical attention if you experience kidney issues.

GLP-1 receptor agonists can trigger or exacerbate restrictive eating behaviors and food aversions, mimicking Avoidant/Restrictive Food Intake Disorder (ARFID), in patients with obesity and those with rare genetic disorders of obesity.

Be aware that GLP-1s can make you lose interest in food entirely. If you find yourself unable to eat enough to maintain your health, or if you develop strong aversions to specific foods, inform your doctor immediately. This may require dose reduction or discontinuation.

Tirzepatide administration is associated with a high frequency of gastrointestinal adverse events (nausea, diarrhea, vomiting) and injection-site reactions, with a median time to onset of 26 days, occurring predominantly during the dose-escalation phase.

If you start Tirzepatide, expect gastrointestinal issues like nausea or diarrhea, especially in the first month. These are common reasons for stopping treatment. Starting at the lowest dose (5mg) might help you tolerate the medication better, as higher doses are linked to later but potentially more severe onset of side effects. Monitor your symptoms closely during the first few weeks.

Older adults (≥65 years) experience adverse events from Tirzepatide significantly earlier (median 12 days) than younger adults (median 31 days), suggesting heightened sensitivity or earlier symptom reporting in this demographic.

If you are over 65 and start Tirzepatide, be extra vigilant in the first two weeks. Side effects like nausea or dizziness may hit you much sooner than they would for a younger person. Report any severe symptoms to your doctor immediately, as discontinuation rates are higher in this age group.

GLP-1 receptor agonist use is associated with an increased risk of hair loss (alopecia, telogen effluvium), with incidence potentially correlated with the magnitude of weight loss.

If you are using a GLP-1 agonist (like Ozempic or Mounjaro) and notice increased shedding or thinning, this is a known potential side effect, often linked to rapid weight loss or hormonal shifts. It does not happen to everyone, and in some cases, hair regrowth has been observed. Do not stop your medication abruptly without consulting your doctor; discuss monitoring strategies or temporary pauses if the hair loss is severe.

Therapeutic inhibition of myostatin using inhibitors or antibodies is a potential treatment for muscle-wasting disorders like Duchenne muscular dystrophy, sarcopenia, and cachexia, but long-term safety and functional integrity are concerns.

Myostatin inhibitors are experimental treatments for serious muscle-wasting diseases. They are not available or recommended for healthy individuals. If you have a wasting disorder, consult a specialist about clinical trials. Do not attempt to self-administer myostatin blockers.

Personalized nutrition does not significantly reduce fasting blood glucose compared to control diets in adults with prediabetes or type 2 diabetes.

While personalized nutrition improves HbA1c and postprandial responses, it may not significantly lower fasting blood glucose compared to standard diets in the short term. Patients should focus on overall glycemic control (HbA1c) rather than just fasting numbers.

Tilorone attenuates high-fat diet-induced hepatic steatosis and improves glucose tolerance in mice by enhancing BMP9-Smad1/5/8 signaling and upregulating PPARγ expression.

This preclinical study suggests that tilorone, administered via intraperitoneal injection, can reduce liver fat and improve glucose metabolism in mice on a high-fat diet by activating specific signaling pathways. However, as this is an animal study using a synthetic small molecule administered via injection, it does not currently provide a direct, actionable protocol for human dietary or lifestyle intervention. Clinical trials are required to determine efficacy and safety in humans.

Liraglutide is associated with higher rates of anxiety and medication switching compared to Tirzepatide and Semaglutide.

If you have a history of anxiety, Liraglutide might not be the best choice, as this study found it was associated with higher anxiety rates and more medication switches compared to Tirzepatide and Semaglutide. Tirzepatide may offer a better balance of efficacy and tolerability for you.